Probing the role of sodium channels in painful neuropathies (PROPANE Study) - PROPANE Study

Medisch Universitair Ziekenhuis Maastricht0 个研究点目标入组 500 人开始时间: 待定最近更新: 2024年4月29日

适应症

试验速览

暂无简介。

•Subjects with Painful PN must meet all of the following inclusion criteria to be eligible for participation:
•a. Fulfillment of the international diagnostic criteria for snall fiber neuropathy, for painful diabetic neuropathy or for chemotherapy induced PN by taxane in breast, ovarian or prostate cancer and oxaliplatin in colon cancer. Patients with CIPN have completed their chemotherapy treatment.
•b. Maximal pain VAS scores must be at least 40 (range: 0 - 100) (without neuropathic pain medication; in case of use of neuropathic pain medication, the VAS-score in the past without medication to the best of patients knowledge will be used)
•c. Age 18 years or older.
•d. Each subject will receive an information leaflet and an informed consent form. Subjects must give informed consent by signing and dating an informed consent form prior to study entry. Subjects must be willing to complete all study-related activities and examination required by the protocol.
•e. For the control groups, maximal pain VAS scores must be less than 40, preferably < 25 (range: 0 - 100).;Healthy controls (n = 20) must meet the following inclusion criteria to be eligible for participation:
•a. Age of 30 - 80 years
•b. Absence of the diagnosis of neuropathy or chronic pain disorders

•Concomitant diseases that might interfere with the interpretations of the results.

发起方

Medisch Universitair Ziekenhuis Maastricht